TRANSFORM - Observational Cohort Study of Darbepoetin Alfa Use in European Union (EU) Hemodialysis Patients Switched From PEG Epoetin Beta
NCT ID: NCT01997892
Last Updated: 2014-06-09
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1027 participants
OBSERVATIONAL
2012-08-31
2013-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Conversion Study From Epoetin Alfa to Monthly Peginesatide Injection in Patients With Chronic Kidney Disease on Dialysis
NCT01478971
Safety and Efficacy of Peginesatide Injection for the Maintenance of Anemia in Chronic Renal Failure Participants Who Are on Hemodialysis or Do Not Require Dialysis and Previously Treated With Darbepoetin Alfa.
NCT00752609
A Dose Conversion Study of Epoetin Alfa in Subjects With the Anemia of Chronic Kidney Disease.
NCT00495365
Treatment for Subjects With Chronic Kidney Disease Receiving Haemodialysis
NCT00116701
A Study of Once Monthly Intravenous or Subcutaneous Mircera in Participants With Chronic Kidney Disease on Hemodialysis.
NCT00717821
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Chronic Kidney Disease (CKD)
Participants with CKD on dialysis and treated with PEG epoetin beta for a minimum of 14 weeks immediately prior to being switched to darbepoetin alfa.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Received PEG epoetin beta for 14weeks prior to switching to darbepoetin alfa and received at least one dose of darbepoetin alfa.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Amgen
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
MD
Role: STUDY_DIRECTOR
Amgen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Edegem, , Belgium
Research Site
Antony, , France
Research Site
Aurillac, , France
Research Site
Béziers, , France
Research Site
Blois, , France
Research Site
Boulogne-sur-Mer, , France
Research Site
Cahors, , France
Research Site
Essey-lès-Nancy, , France
Research Site
Grabels, , France
Research Site
La Réunion, , France
Research Site
La Roche-sur-Yon, , France
Research Site
Libourne, , France
Research Site
Lille, , France
Research Site
Metz, , France
Research Site
Paris, , France
Research Site
Paris, , France
Research Site
Poitiers, , France
Research Site
Saint-Denis de La Réunion, , France
Research Site
Saint-Nazaire, , France
Research Site
Saint-Pierre, , France
Research Site
Saint-Priest-en-Jarez, , France
Research Site
Strasbourg, , France
Research Site
Vandœuvre-lès-Nancy, , France
Research Site
Kiel, , Germany
Research Site
Nordhorn, , Germany
Research Site
Athens, , Greece
Research Site
Athens, , Greece
Research Site
Arnhem, , Netherlands
Research Site
Ribeira, Galicia, Spain
Research Site
Santiago de Compostela, Galicia, Spain
Research Site
Santiago de Compostela, Galicia, Spain
Research Site
Sion, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Donck J, Gonzalez-Tabares L, Chanliau J, Martin H, Stamatelou K, Manamley N, Farouk M, Addison J. Preservation of anemia control and weekly ESA dosage after conversion from PEG-Epoetin beta to darbepoetin alfa in adult hemodialysis patients: the TRANSFORM study. Adv Ther. 2014 Nov;31(11):1155-68. doi: 10.1007/s12325-014-0161-5. Epub 2014 Nov 1.
Related Links
Access external resources that provide additional context or updates about the study.
AmgenTrials clinical trials website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20120126
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.